OBJECTIVES: Previous studies have demonstrated that Electrovestibulography (EVestG) biomarkers for Parkinson's Disease are sensitive to dopamine levels. Given the dopamine hypothesis of Schizophrenia (SCZ), we recorded EVestG signals from 45 individuals with SCZ and 36 healthy controls to evaluate whether EVestG can differentiate these populations.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is early-stage biomarker research in psychiatry with no current implications for audiology clinical practice.
If EVestG biomarkers can reliably index dopamine activity, the inner ear could become a non-invasive window into neuropsychiatric conditions, potentially expanding the role of vestibular assessment beyond audiology.
- 01EVestG biomarkers previously linked to dopamine sensitivity in Parkinson's Disease were tested in schizophrenia.
- 02The study compared schizophrenia patients against healthy controls using inner-ear electrical recordings.
- 03Findings support the hypothesis that EVestG signals reflect dopaminergic system function.
- 04Published in World Journal of Biological Psychiatry; PMID 42947489.
- 05Results are preliminary and not yet applicable to clinical audiology or psychiatric practice.
EVestG biomarkers can differentiate schizophrenia patients from healthy controls.
studypartially supportedEVestG biomarkers are linked to dopamine sensitivity, as previously shown in Parkinson's Disease.
studypartially supported- PMID
- 42947489
- DOI
- 10.1080/15622975.2026.2747936.
- Journal
- World Journal of Biological Psychiatry
- Publication type
- research_article
- Evidence level
- 4
- Population
- Adults with schizophrenia and healthy controls
- Intervention
- Electrovestibulography (EVestG) biomarker assessment
- Comparator
- Healthy controls
Primary outcomes
Differentiation of schizophrenia patients from healthy controls using EVestG biomarkers; Association of EVestG signals with dopaminergic system activity